Drug Trial Radar · NCT01709929
Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Mar 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,287
Actual
Start
Oct 2005
Primary completion
Apr 2006
Study completion Apr 2006
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Oct 18, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in North America. The aim of this trial is to evaluate the safety of insulin detemir for the treatment of diabetes.
Conditions
- Diabetes
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
Interventions
insulin detemirDrug
Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of serious adverse drug reactions (SADRs) including major hypoglycaemic events
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Mississauga, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.